echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves Novartis Egaten for treatment of tablet-sucking disease patients over 6 years of age

    FDA approves Novartis Egaten for treatment of tablet-sucking disease patients over 6 years of age

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    tablet stoma, also known as liver sucking infection, is a neglected tropical diseaseThere are about 2.4 million patients worldwide, and another 180 million people are at risktoday, Novartis(http://announced that the U.SFDA(http://approved the company's egaten (triclabendazole) for the treatment of people over the age of 6Egaten is currently the only recommended treatment by the World Health Organization (WHO) for the treatment of tablet-like schistosomiasis, one of thestandards of the WHO's basicdrug(http:// standardWho provides this drug during an outbreak of tablet stoma and is regularly used in endemic countriesFda approval of Egaten will facilitate the importof of the drug to these disease-endemic countries, ensuring adequate drug stocksTablet stoma has been identified by the FDA as a neglected tropical disease, and this approval gives Novartis a priority review voucherNovartis has donated Egaten to the WHO since 2005 and has helped treat 2 million tablet stoma patients in more than 30 countriesin 2018, Novartis renewed its agreement with the WHO and will continue to donate the drug until 2022 It is expected to be delivered to 300,000 patients each year
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.